Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ValiRxLSE:VAL Days Payable is 517.91 as of Dec. 2025, which is 62% below its 10-year median of 1,366.28. The stock has 4 warning signs investors should review. Among 701 Biotechnology companies, ValiRx ranks better than 87.87% on this metric.
ValiRx's average Accounts Payable for the
six
months ended in Dec. 2025 was £0.11 Mil. ValiRx's Cost of Goods Sold for the
six
months ended in Dec. 2025 was £0.04 Mil.
Hence, ValiRx's Days Payable for the
six
months ended in Dec. 2025 was 517.91.
The historical rank and industry rank for ValiRx's Days Payable or its related term are showing as below:
LSE:VAL'
s Days Payable Range Over the Past 10 Years
Min: 790.83 Med: 1366.28 Max: 13687.5
Current: 1177.21
During the past 13 years, ValiRx's highest Days Payable was 13687.50. The lowest was 790.83. And the median was 1366.28.
LSE:VAL's Days Payable is ranked better than 87.87% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs LSE:VAL: 1177.21
ValiRx's Days Payable
increased
from Dec. 2024 (462.04) to Dec. 2025 (517.91).
It may suggest that ValiRxdelayed paying its suppliers.
ValiRx Days Payable Related Terms
ValiRx Days Payable Historical Data
* Premium members only.
The historical data trend for ValiRx's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:VAL vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, ValiRx's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ValiRx Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ValiRx's Days Payable distribution charts can be found below:
* The bar in red indicates where ValiRx's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
ValiRx's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ValiRx (LSE:VAL) has a Days Payable of 517.91 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ValiRx and its competitors. This is 62% below median its historical median of 1,366.28. Over the past decade, ValiRx's Days Payable has ranged from 790.83 to 13,687.50. According to the industry distribution chart, ValiRx ranks #85 out of 701 companies in the Biotechnology industry, placing it in the top 12.1%.
Is ValiRx's Days Payable too high?
ValiRx's current Days Payable of 517.91 is 62% below median its 10-year median of 1,366.28. Over the past 10 years, this metric has ranged from a low of 790.83 to a high of 13,687.50. The Biotechnology industry median Days Payable is 112.84. ValiRx's value of 517.91 is 359% above this industry median. Based on the distribution chart, ValiRx ranks #85 out of 701 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does ValiRx's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ValiRx ranks #85 out of 701 companies for Days Payable. This places ValiRx in the top 12% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.84. ValiRx's value of 517.91 is 359% above this benchmark. Historically, ValiRx's own Days Payable has ranged from 790.83 to 13,687.50 over the past decade. While the company's 10-year median is 1,366.28 vs. the industry median of 112.84, ValiRx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ValiRx's current Days Payable of 517.91 is 359% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ValiRx and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ValiRx's current Days Payable is 517.91, which is 62% below median its own 10-year median of 1,366.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ValiRx stock overvalued right now?
ValiRx (LSE:VAL) has a current Days Payable of 517.91. The current Days Payable is 517.91, which is 62% below median its 10-year median of 1,366.28 and 359% above the Biotechnology industry median of 112.84. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ValiRx (LSE:VAL), the current Days Payable is 517.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:VAL has been successfully added to your 
